384 related articles for article (PubMed ID: 29061113)
41. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
42. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
43. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
[TBL] [Abstract][Full Text] [Related]
44. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
45. Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.
Fernandes G; Rodrigues A; Matos C; Barata F; Cirnes L; Ferreira L; Lopes JA; Felizardo M; Fidalgo P; Brito U; Parente B
Cancer Treat Res Commun; 2023; 36():100725. PubMed ID: 37321073
[TBL] [Abstract][Full Text] [Related]
46. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing.
Rodon Font N; No Garbarino Y; Díaz Castello O; Moya Amoros J; Barrios Sánchez P; Coroleu Lletget D; Lequerica Cabello MA; Borras Marcet J; Mecho Meca S; Escape I; Martinez-Agea J; Garcia E; Ferrer M; Puig Torrus X
Rev Esp Patol; 2022; 55(3):156-162. PubMed ID: 35779881
[TBL] [Abstract][Full Text] [Related]
47. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
48. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
49. Understanding the Mechanisms of Resistance in
Del Re M; Crucitta S; Gianfilippo G; Passaro A; Petrini I; Restante G; Michelucci A; Fogli S; de Marinis F; Porta C; Chella A; Danesi R
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416192
[TBL] [Abstract][Full Text] [Related]
50. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
51. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
52. Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study.
Bessi S; Pepe F; Russo G; Pisapia P; Ottaviantonio M; Biancalani F; Iaccarino A; Russo M; Biancalani M; Troncone G; Malapelle U
J Clin Pathol; 2023 Mar; 76(3):206-210. PubMed ID: 35701144
[TBL] [Abstract][Full Text] [Related]
53. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
Cox S; Powell C; Morgan S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
[TBL] [Abstract][Full Text] [Related]
54. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
55. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
56. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
58. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
[TBL] [Abstract][Full Text] [Related]
59. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
60. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
